Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma

This article is protected by copyright. All rights reserved.

Source: Pigment Cell Research - September 1, 2017 Category: Cytology Authors: Alain P. Algazi, Rosaura Esteve ‐Puig, Adi Nosrati, Brian Hinds, Adele Hobbs‐Muthukumar, Prachi Nandoskar, Susana Ortiz‐Urda, Paul B. Chapman, Adil Daud Tags: Short Communication Source Type: research